FlexAct® - The new benchmark for operational flexibility
FlexAct® is a new system that enables you to custom- configure single-use solutions for entire biomanufacturing steps. The FlexAct® system consists of the central opera- ting module that offers the widest variety of configuration options so you can take complete control of practically any steps in upstream and downstream processing.
Sartorius Stedim Biotech presents the FlexAct® BP for buffer preparation. Next in line are media preparation (MP), cell harvest (CH), UF | DF crossflow (UD), virus removal (Vr), virus inactivation (VI), polishing (PO), form | fill (FF) and form | transfer (FT).
The core of FlexAct®, the central operating module (COM), has been designed to be used in any application. This means you can quickly reconfigure FlexAct® in just a few easy steps. For example, take the FlexAct® BP for buffer preparation and effortlessly convert it into FlexAct® VR for virus removal.
And it goes without saying that the technologies and products used in FlexAct® are scalable. This makes FlexAct® a future-proof system in every respect; one that gives you the greatest possible flexibility.
Miniature component specialists LEE PRODUCTS have recently published a new EFS (Electro Fluidic Systems) technical handbook which provides a valuable resource of product information along with practical engineering reference material.
Lee Product’s three Electro-Fluidic Systems groups produce high quality miniature solenoid valves, micro-dispense valves, atomising and dispense nozzles, fixed and variable volume pumps, integrated fluidic manifolds, inert tubing and fluid control components and custom engineered designs. These products are used in medical and scientific instrumentation, analytical / clinical chemistry, in-vitro diagnostics, drug discovery and ink jet printing applications.
This new 323 page EFS handbook includes detailed information on Lee’s wide range of solenoid valves and pumps along with their manifolds, tubing, accessories, and special products, plus useful engineering and general information.
More details and copies of the handbook are available from:
Lipocalyx, the provider of the latest transfection technology starts marketing and sales in Great Britain as of today.
The offering will feature the reagents Viromer®Blue and Viromer®Green, critical materials for the work with RNAi. Christian Reinsch, PI at Lipocalyx says: “We knew it is good stuff - but still, it was quite rewarding for us to see Viromers working in other people’s hands. The labs out there used it in challenging experiments and the reality check went really well”.
For the marketing in the UK, Lipocalyx has partnered with Voicentric, a communicator specialized in the life science sector. Steffen Panzner, CEO of Lipocalyx comments: “Expanding the marketing outside Germany was the thing to do and with Voicentric we found a like-minded partner. When we reach out to the scientist, listening and developing solutions is of the same importance to us as presenting the Viromer story. In that regard, we didn’t need to explain much to Voicentric”.
Lipocalyx GmbH, a drug delivery company based in Halle/Saale, Germany started its venture in August 2011 to create entirely novel polymer-based transfectants for oligonucleotides. The team has a strong background in siRNA transfection and chemistry. Lipocalyx received seed financing by IBG RKF II, managed by Goodvent in Magdeburg and High-Tech Gründerfonds (HTGF) in Bonn.
Voicentric Ltd is a marketing agency which specialises in Life-Science and similarly high-tech and research based disciplines. People at Voicentric communicate complex messages - predominantly by telephone - about products and services which improve and facilitate thier research. The company has formed strong ties with the University of Durham.
Sartorius Stedim Biotech, a leading international supplier for the pharma and biotech industries, has launched new sizes XS and S of the Clipster® Aseptic Disconnector, in addition to the existing size L.
Clipster® Aseptic Disconnector makes aseptic tubing disconnection easy.
The Clipster® Aseptic Disconnector XS (yellow), S (red) and L (white) is used after a fluid transfer to disconnect single-use transfer lines and bag assemblies made of silicone or TPE tubes.
This single-use device allows an aseptic disconnection of Silicone (Pt) as well as thermoplastic elastomer (TPE) tubes in biopharmaceutical manufacturing processes. It is safe, quick, easy to use and available as a standalone product or pre-mounted on single-use transfer lines and bag assemblies. The Clipster® Aseptic Disconnector is used after a fluid transfer to disconnect transfer lines and bag assemblies. The disconnection of tubes can be performed in non-classified and classified environments while maintaining product sterility. It is performed with a hand-held tool which ensures easy execution in various space requirements. The Clipster® Aseptic Disconnector XS, S or L can be applied to multiple tubing material (silicone and TPE) and sizes from 1/8”x1/4” up to 1/2” x 3/4”.
The validation of this key single-use device has been carried out under the most stringent test regimes. Biological and physical tests have been combined to provide data representing a variety of process conditions including critical applications.
The PA 800 plus next-generation CE-platform from Beckman Coulter Life Sciences provides automated, quantitative analysis of protein purity, charge isoform distribution and glycan structure.
Beckman Coulter Life Sciences have products offering a range of biotech, analytical chemistry and industrial applications at the Pittcon Conference and Expo, March 18-21, in Philadelphia, USA.
One example of new applications is found with the PA 800 plus next-generation capillary electrophoresis (CE) platform, which provides automated, quantitative analysis of protein purity, charge isoform distribution and glycan structure. Originally designed with biopharmaceutical analysis in mind, the system can also be used in food and beverage quality studies for monosaccharide and protein analysis, and in the quantitative characterization of ions, organic acids and other charged or polar molecules of importance.
Beckman Coulter, Inc., based in California, USA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories on six continents. For more than 75 years, Beckman Coulter products have been making a difference in peoples’ lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and reducing the cost of care. For more information, visit www.beckmancoulter.com.
Hillary Hunter, Beckman Coulter Life Sciences Public Relations
the Wyss Institute for Biologically Inspired Engineering at Harvard University and Sony DADC announced a collaboration that will harness Sony DADC’s global manufacturing expertise to further advance the Institute’s Organs-on-Chips technologies.
Human Organs-on-Chips are composed of a clear, flexible polymer about the size of a computer memory stick, and contain hollow microfluidic channels lined by living human cells – allowing researchers to recapitulate the physiological and mechanical functions of the organs, and to observe what happens in real time. The goal is to provide more predictive and useful measures of the efficacy and safety of new drugs in humans – and at a fraction of the time and costs associated with traditional animal testing.
“We are excited to apply Sony DADC’s deep manufacturing expertise to confront one of the major challenges in the life sciences by helping to accelerate the translation of the Wyss Institute’s Organ-on-Chips from the benchtop to the marketplace,” said Christoph Mauracher, Senior Vice President of the BioSciences division of Sony DADC. “The Organs-on-Chips have the potential to revolutionize testing of drugs, chemicals, toxins and cosmetics.”
This collaboration builds on the momentum the Wyss Institute team has gained recently on its Organs-on-Chips research program. With support from Defense Advanced Research Projects Agency (DARPA)*, National Institutes of Health (NIH), Food and Drug Administration (FDA), and pharmaceutical partners, more than ten Organs-on-Chips are currently under development at the Wyss Institute, including a lung, heart, liver, kidney, bone marrow, and gut-on-a-chip; there is also a major effort to integrate these organ chips into “human body on-chips” that mimic whole body physiology.
In February, Wyss Founding Director Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program, received the prestigious 3Rs Prize from the UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research for the lung-on-a-chip. This month, the Society of Toxicology awarded him the Leading Edge in Basic Science Award for his “seminal scientific contributions and advances to understanding fundamental mechanisms of toxicity.”
“Our work with Sony DADC is a wonderful example of the Wyss Institute model in action,” said Ingber. “We collaborate with industry to help de-risk the technologies we develop, both technically and commercially, and therefore expedite their translation into real world applications.”
*Part of this research was sponsored by the U.S. Army Research Office (ARO) and DARPA; the views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of ARO, DARPA or the U.S. Government.
Wyss Institute for Biologically Inspired Engineering
A novel ophthalmic solution from R-Tech Ueno (Tokyo, Japan) made using Novozymes Biopharma’s recombinant human albumin has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.
Designed by R-Tech Ueno, RU-101 ophthalmic solution is being trialled as a therapy for severe dry eye, for which no effective treatment is currently available. The recombinant human albumin is part of Novozymes Biopharma’s albumin range. Novozymes Biopharma has a strong reputation in the industry for helping customers in the safe and successful commercialization and approval of new products.
The prevalence of severe dry eye, where patients suffer from instability of the tear film, continues to increase. It is the most diagnosed of all ophthalmic disorders and estimates put the market at approximately 1.5 billion USD. The trials for RU-101 ophthalmic solution will move ahead in two stages, the first of which will assess safety using a placebo control, and allow confirmation of the maximum dose. The second stage will then use this maximum dose for 12 weeks to evaluate the safety and effectiveness of RU-101 ophthalmic solution.
Dermot Pearson, Marketing Director at Novozymes Biopharma said, “Novozymes is dedicated to supporting our customers in the drug development and testing stages, and in assisting with the optimisation of their pathways through regulatory approval procedures. We are therefore delighted that RU-101 ophthalmic solution has been approved for clinical testing.”
Novozymes Biopharma’s recombinant albumin is designed to provide quality performance benefits when included in drugs developed by our customers. It was selected as a key component of this novel therapy back in 2011, due to its proven high quality and enhanced safety profile. Animal-free, with an exceptional purity profile and convenient liquid format at room temperature, recombinant albumin delivers consistent levels of quality, leading to reduced lot testing and vendor auditing.
All Novozymes’ recombinant human albumins deliver stable, safe and regulatory compliant ingredients for drug delivery and formulation, and are compliant with the National Formulary (NF) rAlbumin human monograph published by the United States Pharmacopeia (USP).
Thermo Fisher Scientific releases new small benchtop centrifuge, which provides scientists with outstanding capacity in a compact design.
Thermo Fisher Scientific Inc. has launched a new small benchtop centrifuge to meet clinical and research needs alike.
“Centrifuges are in constant use and demand so preventing downtime and bottlenecks is crucial,” said Maurizio Merli, product director, Thermo Fisher Scientific. “With features designed for simplicity, safety and flexibility, the new small benchtop centrifuges can help scientists save time and maximize resources.”
The new centrifuges provide:
Application flexibility, convenient cleaning and ease-of-use with Thermo ScientificAuto-Lock rotor exchange
Versatility to spin blood tubes, conical tubes, microtubes and microplate compatibility with sealing options
One-handed sample protection with Thermo Scientific ClickSeal biocontainment lids, certified by the Public Health Laboratory Service in Porton Down
Intuitive glove and detergent-friendly interface with a bright display, one-touch operation with pre-set protocol options and optional password protection
Sartorius Stedim Biotech develops next generation of its successful single-use laboratory bioreactor.
Proven glass bioreactor design with the efficiency and flexibility of single-use systems
New single-use sensors for non-invasive measurement of the pH and dissolved oxygen
Connection Boxes for BIOSTAT® controllers and other brands of bioreactor controller
Sartorius Stedim Biotech (SSB), a leading international equipment provider for the biopharmaceutical industry, presents UniVessel® SU, the second generation of its successful single-use bioreactor. This single-use stirred tank bioreactor can be operated in a choice of working volumes ranging from 0.6L to 2L, and is suitable for the cultivation of mammalian cells, including stem cells, insect and plant cells. Typical areas of application for the UniVessel® SU are process development and optimization, as well as production of seed cultures and cell banks.
Fast and flexible for efficient management of peak workloads despite challenging timelines UniVessel® SU combines the proven design of conventional glass vessels with the efficiency and flexibility of single-use systems. Supplied as a completely preassembled and presterilized unit, this laboratory bioreactor is instantly ready to use right out of the box. It eliminates the need for labor-intensive steps, such as autoclaving or installation of probes, minimizing the time needed for preparation. The new UniVessel® SU can be used interchangeably with glass vessels to help laboratories better manage peak workloads despite challenging timelines.
Single-use sensors for non-invasive measurement of pH and dissolved oxygen Each UniVessel® SU is equipped with integrated single-use sensors for pH and dissolved oxygen measurement. This proven single-use sensor technology, which SSB also uses in its BIOSTAT® RM and BIOSTAT® STR disposable bioreactors, measures the pH and DO values non-invasively, thus eliminating time-consuming autoclaving and risk-prone insertion of probes in the culture vessel.
Connection Boxes interface UniVessel® SU with existing bioreactor controllers UniVessel® SU is compatible with SSB BIOSTAT® controllers and can also be operated with nearly any other brand of bioreactor controller. This saves customers from having to buy expensive new equipment. The new UniVessel® SU Connection Box enables the integrated single-use sensors of UniVessel® SU to be used with existing controllers. Up to four bioreactor controllers can be interfaced per Connection Box. The sensor calibration data can be read in easily by a barcode scanner in an error-free manner.
PromoKine is now adding more than 200 new ELISA kits for target molecules which play integral roles in cell signaling research.
PromoKine currently offers ~400 ELISA kits for detecting and quantifying the "free" forms of human, mouse, rat, monkey and pig cytokines, growth factors and other cell biology target molecules in cell culture supernatants, plasma, serum and other body fluids. Some can even be used with tissue lysates! Our ready-to-use ELISA kits are very convenient, including a user-friendly and easy-to-follow protocol along with all the necessary components to perform a highly sensitive, reliable and reproducible ELISA.
In addition, we also provide cost-effective ELISA Development Kits containing all required reagents to assay your target protein/peptide in ten 96-well microtiter plates (approximately 1,000 assays per kit).
PromoKine is now adding more than 200 new ELISA kits for target molecules which play integral roles in cell signaling research; such as diverse interleukins, FGFs, CD markers, BMPs, MIPs, MMPs and MCPs as well as Activin A, beta-NGF, Cardiotrophin, Lymphotactin, Oncostatin M, Insulin and several other hormones. We also have launched a new line of Cell-based Phosphorylation ELISAs.
Along with this, we are extending our comprehensive product line of recombinant cytokines, growth factors, soluble receptors, hormones and other proteins/peptides involved in cell signaling as well as our wide range of antibodies against these molecules.
Olympus will exhibit its BX3 upright microscope systems and VS120 virtual slide scanner at ECP 2013.
Designed specifically to meet the needs of a range of pathology applications, the systems ensure robust diagnosis and discovery alongside ergonomic operation.
Enhancing the workflow of research and diagnostic centres alike, the latest range of Olympus pathology microscope systems and accessories will be on show at the 25th European Congress of Pathology (ECP) 2013, 31 August – 4 September in Lisbon, Portugal. Delegates can visit booth 14 to view the Olympus BX3 range of upright microscopes and the Olympus VS120 virtual slide scanner.
The BX3 range of upright microscope offers complete flexibility in pathology applications due to a modular design. Ergonomics is a priority, and each user can set up the microscope to match their posture, for both comfort and convenience. The range includes several models focused on either clinical or research microscopy, and delegates of ECP will have a chance to view the fully automated BX63, the research-focused BX53 and the BX43 clinical imaging system.
The BX63 delivers high performance automated microscopy for research applications, and the system on display at booth 14 will also feature the unique dual chip Olympus DP80 digital camera. Combining colour and monochrome chips within the same housing allows joint colour and fluorescent imaging in pathology applications, for example when combining histological staining with fluorescent dyes on the same sample. The BX3 range lends itself to easy integration into existing workflows, and visitors can also discover how the BX43 clinical microscope is compatible with both third party cameras and software.
With a modular design, the research-focused BX53 can be easily customised and the system on display at ECP will feature the Olympus discussion tube unit. Allowing multiple users to observe the same specimen using separate eyepieces, this system is ideal for both teaching and consulting, as all users see the actual image, not a digital representation. The unit is a powerful tool for reviewing difficult cases with other pathologists and colleagues to discuss diagnoses, and delegates of ECP are invited to bring along their own samples to examine with colleagues.
Also on display will be the Olympus VS120 virtual slide scanner, which features the flexibility, resolution and image quality necessary for meeting the demands of pathology research workflows. The system creates a “virtual slide” high-resolution image of the complete specimen at a range of magnifications, which can be electronically stored on a central server. This enables instant access and simultaneous viewing anywhere in the world, omitting the need to transport specimens between laboratories, reducing slide archives and securing a permanent digital record of the sample.
Delegates will discover how the latest in Olympus imaging technology enables new possibilities for clinical and research pathology applications alike.